Although 18 F-fluorodeoxyglucose positron emission tomography (18 F-FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end-of-treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five-year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five-year progression-free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order early metabolic responder (iPETneg → ePETneg ), delayed responder (iPETpos → ePETneg ), loss-metabolic responder (iPETneg → ePETpos ), and never-metabolic responder (iPETpos → ePETpos ). In the autologous haematopoietic stem cell transplantation (auto-HSCT)-fit subgroup, OS was more favourable in the order early metabolic responders, delayed metabolic responders, and non-metabolic responders, with a marginal trend toward statistical significance (HR 3·41, P = 0·051), and PFS was significantly superior in early metabolic responders (HR 4·43, P = 0·002). In a group that was ineligible for auto-HSCT, OS and PFS were significantly superior in early metabolic responders. Our results suggested that iPET is of prognostic value and an independent predictor of survival in MCL patients receiving frontline R-CHOP. Therefore, prospective clinical trials of iPET-guided treatment strategies for these patients are warranted.

中文翻译：

---

正电子发射断层扫描对一线R-CHOP治疗的套细胞淋巴瘤患者的预后影响。

尽管18 F-氟脱氧葡萄糖正电子发射断层显像（18 F-FDG PET）通常用于侵袭性淋巴瘤的初始分期和治疗反应评估，但其对套细胞淋巴瘤（MCL）的预后效用仍存在争议。因此，我们回顾性评估了在前线R-CHOP（利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙）治疗的89例连续晚期MCL患者中，临时PET（iPET）和治疗结束PET（ePET）反应与生存结局的相关性。 。iPET阳性与较低的五年总体生存率（OS）[危险比（HR）7·84，P <0·0001]和较差的五年无进展生存率（PFS）密切相关（HR 3·34，P <0·0001）。OS和PFS对早期代谢反应者（iPETneg→ePETneg）的顺序更有利，延迟响应者（iPETpos→ePETneg），损失代谢响应者（iPETneg→ePETpos）和永不代谢响应者（iPETpos→ePETpos）。在自体造血干细胞移植（auto-HSCT）适应亚组中，按早期代谢反应，延迟代谢反应和非代谢反应的顺序排列，OS更为有利，且具有统计学上的显着趋势（HR 3·41， P = 0·051），而PFS在早期代谢反应者中显着优于对照组（HR 4·43，P = 0·002）。在不适合进行自动HSCT的人群中，OS和PFS在早期代谢反应者中显着优于对照组。我们的结果表明，iPET在接受一线R-CHOP治疗的MCL患者中具有预后价值和独立的生存预测因子。所以，